{"title":"Evolving New Forms of Treatment","authors":"Ramón Cacabelos","doi":"10.2174/187152492401240307100421","DOIUrl":"https://doi.org/10.2174/187152492401240307100421","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":9799,"journal":{"name":"Central nervous system agents in medicinal chemistry","volume":"58 20","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140356753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aditya Singh, Shubhra Maheshwari, Jagat Pal Yadav, Aditya Prakash Varshney, Sudarshan Singh, Bhupendra G. Prajapati
{"title":"A Review on Tau Targeting Biomimetics Nano Formulations: Novel\u0000Approach for Targeting Alzheimer's Diseases","authors":"Aditya Singh, Shubhra Maheshwari, Jagat Pal Yadav, Aditya Prakash Varshney, Sudarshan Singh, Bhupendra G. Prajapati","doi":"10.2174/0118715249289120240321065936","DOIUrl":"https://doi.org/10.2174/0118715249289120240321065936","url":null,"abstract":"\u0000\u0000Central nervous system disorders are prevalent, profoundly debilitating, and poorly\u0000managed. Developing innovative treatments for these conditions, including Alzheimer's disease,\u0000could significantly improve patients' quality of life and reduce the future economic burden on\u0000healthcare systems. However, groundbreaking drugs for central nervous system disorders have\u0000been scarce in recent years, highlighting the pressing need for advancements in this field. One significant\u0000challenge in the realm of nanotherapeutics is ensuring the precise delivery of drugs to their\u0000intended targets due to the complex nature of Alzheimer's disease. Although numerous therapeutic\u0000approaches for Alzheimer's have been explored, most drug candidates targeting amyloid-β have\u0000failed in clinical trials. Recent research has revealed that tau pathology can occur independently of\u0000amyloid-β and is closely correlated with the clinical progression of Alzheimer's symptoms. This\u0000discovery suggests that tau could be a promising therapeutic target. One viable approach to managing\u0000central nervous system disorders is the administration of nanoparticles to neurons, intending to\u0000inhibit tau aggregation by directly targeting p-tau. In Alzheimer's disease, beta-amyloid plaques\u0000and neurofibrillary tau tangles hinder neuron transmission and function. The disease also triggers\u0000persistent inflammation, compromises the blood-brain barrier, leads to brain shrinkage, and causes\u0000neuronal loss. While current medications primarily manage symptoms and slow cognitive decline,\u0000there is no cure for Alzheimer's.\u0000","PeriodicalId":9799,"journal":{"name":"Central nervous system agents in medicinal chemistry","volume":" 78","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140384591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}